Mereo BioPharma Group plc MREO
0.30 USD 0.00 (+0.46%)
Nov 5, 2026, 9:41 AM EST
0.2902 Day range 0.3129
0.20 52-week range 2.37
- YTD
- -26.98%
- 1 year
- -82.89%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
benzinga.com Mereo BioPharma Group Q2 EPS $(0.01), Inline Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Mereo BioPharma Group Q1 EPS $(0.01), Inline Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Mereo BioPharma Group Q4 EPS $(0.01), Inline Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com BTIG Reiterates Buy on Mereo BioPharma Group, Maintains $1 Price Target BTIG analyst Julian Harrison reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $1 price target.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Five Below To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday - benzinga.com Needham Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $3 Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $5 to $3.
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Why OceanFirst Financial Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session 
benzinga.com This Mereo BioPharma Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday 
benzinga.com CapsoVision, ACM Research And Other Big Stocks Moving Higher On Tuesday 
benzinga.com Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain Ultragenyx stock closed 42% lower on Monday as from Phase 3 studies for setrusumab in OI revealed no statistical significance.
benzinga.com State Street To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday 
benzinga.com Jefferies Downgrades Mereo BioPharma Group to Hold, Lowers Price Target to $0.5 Jefferies analyst Maury Raycroft downgrades Mereo BioPharma Group (NASDAQ:MREO) from Buy to Hold and lowers the price target from $7 to $0.5.
benzinga.com Nasdaq Falls Over 100 Points Amid Decline In Tech Stocks: Investor Sentiment Weakens, Fear & Greed Index In 'Neutral' Zone U.S. stocks fell on Monday, with Nasdaq down 100 points. Nvidia Corp. and Mereo BioPharma Group plc also experienced declines.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com BTIG Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $1 BTIG analyst Julian Harrison maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $6 to $1.- benzinga.com LifeSci Capital Downgrades Mereo BioPharma Group to Market Perform LifeSci Capital analyst Cory Jubinville downgrades Mereo BioPharma Group (NASDAQ:MREO) from Outperform to Market Perform.
benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
benzinga.com Silver Tumbles 8%; Society Pass Shares Spike Higher - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Dow Falls Over 100 Points; US Pending Home Sales Rise In November 
benzinga.com Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta treatment.
benzinga.com Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Ultragenyx Pharmaceutical And Its Partner Mereo Biopharma's Phase 3 Orbit And Cosmic Studies For Setrusumab (UX143) In Osteogenesis Imperfecta Did Not Achieve Statistical Significance Against Reduction In Annualized Clinical Fracture Rate Compared To Placebo Or Bisphosphonates, Respectively Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic)Both studies achieved the secondary endpoint of…
benzinga.com Needham Reiterates Buy on Mereo BioPharma Group, Maintains $5 Price Target Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $5 price target.- benzinga.com BTIG Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target BTIG analyst Julian Harrison reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.
- benzinga.com JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8 JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and raises the price target from $7 to $8.
- benzinga.com Mereo BioPharma Group Q2 EPS $(0.02) Misses $(0.01) Estimate, Sales $500.000K Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is unchanged from the same period last…
benzinga.com Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings 
benzinga.com US Stocks Mixed; Initial Jobless Claims Fall 
benzinga.com Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - benzinga.com Needham Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $5 Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $7 to $5.
benzinga.com Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Ultragenyx And Mereo BioPharma To Complete Phase 3 UX143 Trials In Osteogenesis Imperfecta By Year-End; Data Monitoring Committee Supports Continued Study With Safety Profile Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO), today announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143…